Long-term treatment with growth hormone has no persisting effect on lipoprotein(a) in patients with Turner's syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 3, 1999, Pages 967-970

  Querfeld, Uwe ^c   Dopper S ^d   Gradehand, A ^d   Kiencke, P ^a   Wahn, F ^d   Zeisel, H J ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Clinical Research Institute   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; HUMAN GROWTH HORMONE; LIPOPROTEIN A; OXANDROLONE;

ADOLESCENT; ARTICLE; BODY HEIGHT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; FEMALE; HORMONAL THERAPY; HORMONE ACTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBERTY; RISK FACTOR; SCHOOL CHILD; TURNER SYNDROME;

EID: 0343194448     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.3.5516     Document Type: Article

References (37)

1. Saenger P. 1996 Turner's syndrome. N Engl J Med. 335:1749-1754.
2. van den Broeck J, Massa GG, Attanasio A, et al. 1995 Final height after long-term growth hormone treatment in Turner syndrome. J Pediatr. 127:729-735.
3. Ross JL, Feuillan P, Long LM, Kowal K, Kushner H, Cutler GBJ. 1994 Lipid abnormalities in Turner syndrome. J Pediatr. 126:242-245.
4. Gravholt CH, Naerra RW, Nyholm B, et al. 1998 Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. Diabetes Care. 21:1062-1070.
5. Wilson PW, Evans JC. 1993 Coronary artery disease prediction. Am J Hypertens. 6:309S-313S.
6. Berenson GS, Srinivasan SR, Bao W, Newman III WP, Tracy RE, Wattigney WA. 1998 Assocation between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 338:1656.
7. Scanu A, Fless GM. 1990 Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest. 85:1709-1715.
8. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AMJ. 1986 Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by coronary angtography. Circulation. 74:758-765.
9. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. 1990 Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 36:20-23.
10. Lackner C, Cohen JC, Hobbs HH. 1993 Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 2:993-940.
11. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. 1992 Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 90:52-60.
12. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA. 1993 Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL-cholesterol concentrations. Arteriosder Thromb. 13:296-301.
13. Tonstad S, Sundt E, Ose L, et al. 1996 The effect of growth hormone on low density lipoprotein cholesterol and lipoprotein(a) levels in familial hypercholesterolemia. Metabolism. 45:1415-1421.
14. Nolte W, Rädisch C, Armstrong VW, Hüfner M, Von zur Mühlen A. 1997 The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults wih acquired GH deficiency: results of a double-lind and placebo-controlled trial. Eur J Endocrinol. 137:459-466.
15. Querfeld U, Haffner D, Wühl E, et al. 1996 Treatment with growth hormone increases lipoprotein(a) serum levels in children with chronic renal insufficiency. Eur J Pediatr. 155:913-918.
16. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. 1997 Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol. 136:377-381.
17. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. 1997 Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endodocrinol Metab. 82:550-555.
18. Russel-Jones DL, Watts GF, Weissberger A, et al. 1993 The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone-deficient patients. Clin Endocrinol (Oxf). 41:345-350.
19. Hassan HMS, Kohno H, Kuromaru R, Honda S, Ueda K. 1996 Body composition, atherogenic risk factors and apolipoproieins following growth hormone treatment. Acta Paediatr. 85:899-901.
20. Webster JM, Stewart M, Al-Maskari M, et al. 1997 The effect of growth hormone replacement therapy for up to 12 months on lipoprotein(a) in growth hormone-deficient adults. Atherosclerosis. 133:115-121.
21. Tam SCF, Pang RWC, Janus ED, Kwan EYW, Low LCK. 1997 Growth hormone therapy transiently increases apolipoprotein(a) in short β-thalassaemia major children with normal growth hormone reserve. Atherosclerosis. 128:175-182.
22. Soma MR, Baetta R, Crosignani P. 1997 The menopause and lipid metabolism: strategies for cardiovascular disease prevention. Curr Opin Lipidol. 8:229-235.
23. Henriksson P, Angelin B, Berglund L. 1992 Hormonal regulation of serum Lp(a) levels. J Clin Invest. 89:1166-1171.
24. Stahnke N, Stubbe P, Keller E. 1992 Recombinant human growth hormone and oxandrolone in treatment of short stature in girls with Turner syndrome. Horm Res. 37:37-46.
25. Stahnke N, Stubbe P, Keller E, Heisel HJ, Serono Study Group Hamburg. 1991 Effects and side-effects of GH plus oxandrolone in Turner syndrome. In: Ranke MB, Rosenfeld RG, eds. Turner syndrome: growth promoting therapies. Amsterdam: Excerpta Medica; 241-247.
26. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. 1987 Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 80:458-465.
27. Frison L, Pocock SJ. 1992 Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 11:1685-1704.
28. Chow S-C, Liu J-P. 1998 Analysis of continuous data. In: Chow S-C, Liu J-P, eds. Design and analysis of clinical trials. Concepts and methodologies, 1st ed. New York: Wiley and Sons; 259-305.
29. Lanes R, Gunczler P, Palacios A, Villaroel O. 1997 Serum lipids, lipoprotein lp(a), and plasminogen activator inhibitor-1 in patients with Turner's syndrome before and during growth hormone and estrogen therapy. Fertil Steril. 68:473-477.
30. Johansson G, Oscarsson J, Rosen T, et al. 1995 Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and apo(a) and apo(E) phenotypes. Arterioscler Thomb Vasc Biol. 15:2142-2150.
31. Mooser V, Hobbs HH. 1997 Lipoprotein(a) and growth hormone: is the puzzle solved? Eur J Endocrinol. 137:450-452.
32. Kronenberg F, Utermann G, Dieplinger H. 1996 Lipoprotein(a) in renal disease. Am J Kidney Dis. 27:1-25.
33. Olivecrona H, Ericsson S, Berglund L, Angelin B. 1993 Increased concentrations of serum lipoprotein(a) in response to growth hormone treatment. Br Med J. 306:1726-1727.
34. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. 1996 Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol. 16:1568-1572.
35. Evans RW, Sankey SS, Hauth BA, Sutton-Tyrrell K, Kamboh MI, Kuller LH. 1996 Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay. Lipids. 31:1197-1203.
36. Craig WY, Poulin SE, Forster NR, Neveux LM, Wald NJ, Ledue TB. 1992 Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits. Clin Chem. 38:550-553.
37. Sgoutas DS, Tuten T. 1992 Effect of freezing and thawing of serum on the immunoassay of lipoprotein(a). Clin Chem. 38:1873-1877.